| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2017-02-24 01:29:40 UTC |
|---|
| Update Date | 2022-03-07 03:17:50 UTC |
|---|
| HMDB ID | HMDB0062195 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Platelet-activating factor |
|---|
| Description | Platelet-activating factor, also known as PAF and PC(O-16:0/2:0), is a ubiquitous, potent phospholipid activator and mediator of inflammation that has an important role in the pathogenesis of inflammatory disorders and cardiovascular disease. PAF is able to cause platelet aggregation and anaphylaxis. PAF is synthesized continuously in low quantities in many different types of cells, but especially those involved in host defence, such as macrophages, monocytes, granulocytes, neutrophils, platelets, and endothelial cells. Platelet-activating factor receptor (PAFR) is a G-protein coupled receptor (GPCR) located on the cell membranes of a variety of cells. Once bound to its receptor, PAF mobilizes calcium and activates a wide range of signalling pathways (e.g. phospholipase C-mediated signalling (PMID: 26616844 ). |
|---|
| Structure | CCCCCCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(C)=O InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (R)-7-(Acetyloxy)-4-hydroxy-N,N,N-trimethyl-3,5,9-trioxa-4-phosphapentacosan-1-aminium hydroxide inner salt 4-oxide | ChEBI | | 1-Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine | ChEBI | | 1-O-Hexadecyl paf | ChEBI | | 1-O-Hexadecyl-2-acetyl-sn-glycero-3-phosphocholine | ChEBI | | 1-O-Hexadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine | ChEBI | | 1-O-Hexadecyl-2-O-acetyl-sn-glycero-3-phosophocholine | ChEBI | | 1-O-Hexadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine | ChEBI | | 1-O-Hexadecyl-platelet-activating factor | ChEBI | | C16 PAF | ChEBI | | C16-PAF | ChEBI | | C16:0 PAF | ChEBI | | PAF | ChEBI | | Platelet activating factor | ChEBI | | Platelet-activating factor | ChEBI | | Platelet-activating factor C16 | ChEBI | | 1-Hexadecyl-2-acetyl-glycerophosphocholine | HMDB | | APRL | HMDB | | Hexadecyl-paf-acether | HMDB | | 1-Hexadecyl-2-acetyl-glycero-3-phosphocholine | HMDB | | HD-PAF | HMDB | | PAF-16 CPD | HMDB | | HAG-PC | HMDB | | HAGPC | HMDB | | Antihypertensive polar renomedullary lipid | HMDB | | Aggregating factor, platelet | MeSH | | PAF-acether | MeSH | | Phosphorylcholine, acetyl glyceryl ether | MeSH | | Platelet-activating substance | MeSH | | AGEPC | MeSH | | Platelet activating substance | MeSH | | Platelet aggregation enhancing factor | MeSH | | Factor, platelet activating | MeSH | | PAF acether | MeSH | | Thrombocyte aggregating activity | MeSH | | 1 Alkyl 2 acetyl sn glycerophosphocholine | MeSH | | 1-Alkyl-2-acetyl-sn-glycerophosphocholine | MeSH | | Acetyl glyceryl ether phosphorylcholine | MeSH | | Platelet aggregating factor | MeSH | | 1-Hexadecyl-2-acetyl-GPC | HMDB | | 1-Hexadecyl-2-acetyl-sn-glycero-phosphatidylcholine | HMDB | | 1-O-Hexadecyl-2-O-acetyl-sn-glycero-3-phosphocholine | HMDB | | 1-O-Hexadecyl-2-acetyl-sn-glycerophosphocholine | HMDB | | Acetyl-glyceryl-ether-phosphorylcholine | HMDB | | Blood platelet-activating factor | HMDB | | Blood platelet-activating factor acether | HMDB | | C16-PAF acether | HMDB | | GPC(16:0/2:0) | HMDB | | GPC(18:0) | HMDB | | GPC(O-16:0/2:0) | HMDB | | GPCho(16:0/2:0) | HMDB | | GPCho(18:0) | HMDB | | GPCho(O-16:0/2:0) | HMDB | | PAF 16 | HMDB | | PAF C 16 | HMDB | | PC(16:0/2:0) | HMDB | | PC(18:0) | HMDB | | PC(O-16:0/2:0) | HMDB | | Phosphatidylcholine(16:0/2:0) | HMDB | | Phosphatidylcholine(18:0) | HMDB | | Phosphatidylcholine(O-16:0/2:0) | HMDB | | Platelet-activating factor (1-O-hexadecyl) | HMDB | | Platelet-activating factor acether | HMDB |
|
|---|
| Chemical Formula | C26H54NO7P |
|---|
| Average Molecular Weight | 523.6832 |
|---|
| Monoisotopic Molecular Weight | 523.363789599 |
|---|
| IUPAC Name | (2-{[(S)-((2R)-2-(acetyloxy)-3-(hexadecyloxy)propyl phosphono)]oxy}ethyl)trimethylazanium |
|---|
| Traditional Name | (2-{[(S)-((2R)-2-(acetyloxy)-3-(hexadecyloxy)propyl phosphono)]oxy}ethyl)trimethylazanium |
|---|
| CAS Registry Number | 74389-68-7 |
|---|
| SMILES | CCCCCCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(C)=O |
|---|
| InChI Identifier | InChI=1S/C26H54NO7P/c1-6-7-8-9-10-11-12-13-14-15-16-17-18-19-21-31-23-26(34-25(2)28)24-33-35(29,30)32-22-20-27(3,4)5/h26H,6-24H2,1-5H3/t26-/m1/s1 |
|---|
| InChI Key | HVAUUPRFYPCOCA-AREMUKBSSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 1-alkyl,2-acetylglycero-3-phosphocholines. These are glycerophosphocholines that carry exactly one acetyl chain attached to the glycerol moiety through an ester linkage at the O2-position, and one alkyl chain attached through an ether linkage at the O1-position. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Glycerophospholipids |
|---|
| Sub Class | Glycerophosphocholines |
|---|
| Direct Parent | 1-alkyl,2-acetylglycero-3-phosphocholines |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1-alkyl,2-acetylglycero-3-phosphocholine
- Phosphocholine
- Glycerol ether
- Dialkyl phosphate
- Organic phosphoric acid derivative
- Phosphoric acid ester
- Alkyl phosphate
- Tetraalkylammonium salt
- Quaternary ammonium salt
- Carboxylic acid ester
- Carboxylic acid derivative
- Dialkyl ether
- Ether
- Monocarboxylic acid or derivatives
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Carbonyl group
- Amine
- Organic nitrogen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organic salt
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.00022 g/l | ALOGPS | | LogP | 2.71 | ALOGPS |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 10.16 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 19.8199 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.05 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3183.1 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 190.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 259.8 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 169.4 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 432.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 980.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 866.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 562.9 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 2259.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 653.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 2337.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 568.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 562.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 202.6 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 90.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Platelet-activating factor GC-MS (Non-derivatized) - 70eV, Positive | splash10-000t-7920100000-1c445dd863672863393f | 2016-09-22 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Platelet-activating factor , positive-QTOF | splash10-001i-1912020000-cd0b0948116f9c94f643 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 10V, Negative-QTOF | splash10-0a4i-0000090000-70514fe85c8e3c0890ea | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 20V, Negative-QTOF | splash10-0a4i-0000090000-70514fe85c8e3c0890ea | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 40V, Negative-QTOF | splash10-0a4j-5001920000-fed72cb85f07c7623fbe | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 10V, Negative-QTOF | splash10-00di-2000090000-17c9524659f9c78dd8aa | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 20V, Negative-QTOF | splash10-0a4i-9000010000-a0c661c1c6e6ea6501cc | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 40V, Negative-QTOF | splash10-0a4i-9000000000-e49acc579337dc9681c0 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 10V, Positive-QTOF | splash10-00di-0000090000-cb20f2bc7d50322718cf | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 20V, Positive-QTOF | splash10-00di-0000090000-cb20f2bc7d50322718cf | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Platelet-activating factor 40V, Positive-QTOF | splash10-0089-1913460000-d473e16780d273cab196 | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487 ]
- Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res. 2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246 ]
- Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007 Mar 20. [PubMed:17374880 ]
- Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621. [PubMed:20044567 ]
- Divecha N, Irvine RF: Phospholipid signaling. Cell. 1995 Jan 27;80(2):269-78. [PubMed:7834746 ]
- Kelesidis T, Papakonstantinou V, Detopoulou P, Fragopoulou E, Chini M, Lazanas MC, Antonopoulou S: The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. AIDS Rev. 2015 Oct-Dec;17(4):191-201. [PubMed:26616844 ]
- Cevc, Gregor (1993). Phospholipids Handbook. Marcel Dekker.
- Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
|
|---|